Latest News - McKesson
Top Corporates Hub
McKesson
Nanoscope Therapeutics Selects InspiroGene by McKesson to Support Distribution of Novel Retinal Therapy
27.05.2026 11:00
Nanoscope Therapeutics Inc., a biotechnology company focused on developing and commercializing novel, disease‑agnostic therapies for patients with photoreceptor loss and vision impairment due to retinal degeneration, today announced that it has selected InspiroGene by McKesson to provide U.S. commercialization services for its lead product, MOGENRY™, subject to U.S. regulatory approval.
A Look Back at Healthcare Providers & Services Stocks’ Q1 Earnings: McKesson (NYSE:MCK) Vs The Rest Of The Pack
22.05.2026 19:08
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at McKesson (NYSE:MCK) and its peers.
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
22.05.2026 16:16
McKesson's oncology growth, GLP-1 momentum and RxTS expansion support earnings strength, but pricing reform and margin pressures pose risks.
TBRG Posts Q1 Earnings: How to Play the Stock Amid Pending Sell-off?
22.05.2026 14:13
TruBridge climbs after Q1 EPS beats estimates and an IKS Health buyout deal sets a $26.25-per-share cash offer for shareholders.
Are Wall Street Analysts Predicting McKesson Stock Will Climb or Sink?
22.05.2026 13:44
McKesson has underperformed the broader market over the past year, but analysts are highly optimistic about the stock’s prospects.
Ontada Integrates Florida Cancer Specialists & Research Institute Data to Enrich Its Data Ecosystem
21.05.2026 12:00
BOSTON, May 21, 2026--Ontada®, a business for oncology insights, announced the inclusion of Florida Cancer Specialists & Research Institute's data into its ecosystem.
What Makes McKesson Corporation (MCK) an Attractive Bet?
20.05.2026 13:26
TCW Funds, an investment management firm, published its first-quarter 2026 investor letter for the ‘TCW Concentrated Large Cap Growth Fund.’ A copy of the letter is available to download here. The first quarter was marked by volatility in equity markets, driven by geopolitical tensions, concerns about the private credit sector, a government shutdown, and ongoing […]
1 S&P 500 Stock to Target This Week and 2 We Avoid
18.05.2026 08:36
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
5 Insightful Analyst Questions From McKesson’s Q1 Earnings Call
17.05.2026 15:48
McKesson’s first quarter results fell short of analyst revenue expectations, with management attributing the shortfall to lower branded pharmaceutical revenues, including manufacturer price declines and a sequential dip in GLP-1 medication volumes. Despite these headwinds, sales grew year over year, supported by strength in specialty pharmaceutical distribution and expanded provider networks in oncology and multispecialty. CEO Brian Tyler acknowledged the impact of the Inflation Reduction Act’s
How The Evolving Story On McKesson (MCK) Is Shaping Its Valuation Outlook
14.05.2026 04:37
McKesson’s fair value estimate has been trimmed from US$990.87 to US$951.73, a reduction of about 4% in the latest model update. That shift lines up with a Street backdrop where some analysts are cutting price targets while others still point to upside from newer business lines. This leaves you with a more mixed signal on the stock’s risk and reward profile. Read on to see how these revised targets fit into the broader narrative and how you can keep track as views continue to evolve. Stay...
Can CAH Sustain Growth on Booming Pharmaceutical & Specialty Segment?
13.05.2026 14:40
Cardinal Health's Pharmaceutical & Specialty segment posts strong Q3 growth, but can specialty momentum continue powering earnings?
PRISM Vision Group Continues to Enhance Eye Care Through Retina Macula Institute Partnership
13.05.2026 12:00
NEW PROVIDENCE, N.J., May 13, 2026--PRISM Vision Group announced that it closed a transaction with Retina Macula Institute, through which RMI joins its network of affiliated practices.
MCK Q1 Deep Dive: Revenue Misses Analyst Expectations as Margin Initiatives Continue
13.05.2026 04:20
Healthcare distributor and services company McKesson (NYSE:MCK) fell short of the market’s revenue expectations in Q1 CY2026, but sales rose 6% year on year to $96.3 billion. Its non-GAAP profit of $11.69 per share was 1.1% above analysts’ consensus estimates.
[Latest] Global Clinical Informatics Market Size/Share Worth USD 962.41 Billion by 2035 at a 13.36% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
12.05.2026 08:30
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Clinical Informatics Market size & share revenue was valued at approximately USD 274.64 Billion in 2025 and is expected to reach USD 311.33 Billion in 2026 and is expected to reach around USD 962.41 Billion by 2035, at a CAGR of 13.36% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Koninklijke Philips
McKesson Corporation Just Beat EPS By 9.0%: Here's What Analysts Think Will Happen Next
11.05.2026 10:43
McKesson Corporation ( NYSE:MCK ) shareholders are probably feeling a little disappointed, since its shares fell 8.9...
MCK Stock Falls Despite Q4 Earnings Beat, Sales Miss, Margins Up
08.05.2026 14:47
McKesson beats Q4 EPS estimates as oncology and specialty distribution growth offset revenue miss and lift segment margins.
Does McKesson's (MCK) Bigger Credit Line Quietly Redefine Its Capital Allocation Priorities?
08.05.2026 07:20
In the past quarter, McKesson Corporation reported fourth-quarter fiscal 2026 sales of US$96.30 billion and net income of US$1.68 billion, with full-year sales reaching US$403.43 billion and net income of US$4.76 billion, alongside a new US$5.00 billion multi-currency revolving credit facility maturing in 2031. The combination of higher earnings per share from continuing operations and expanded committed liquidity gives investors more information about McKesson’s capacity to fund operations,...
McKesson : Annual Report for Fiscal Year Ending 03-31, 2026 (Form 10-K)
08.05.2026 06:07
Management's Discussion and Analysis of Financial Condition and Results of Operations. INDEX TO MANAGEMENT'S DISCUSSION AND ANALYSIS ...
Do McKesson's (NYSE:MCK) Earnings Warrant Your Attention?
03.05.2026 14:00
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...
McKesson (MCK) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
30.04.2026 14:00
McKesson (MCK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.